• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

作者信息

Gentile Massimo, Shanafelt Tait D, Reda Gianluigi, Mauro Francesca Romana, Zirlik Katja, Ciolli Stefania, Laurenti Luca, Del Principe Maria Ilaria, Rossi Davide, Di Renzo Nicola, Molica Stefano, Angrilli Francesco, Coscia Marta, Chiarenza Annalisa, Giordano Annamaria, Cutrona Giovanna, Chaffee Kari G, Parikh Sameer A, Uccello Giuseppina, Innocenti Idanna, Tripepi Giovanni, D'Arrigo Graziella, Vigna Ernesto, Recchia Anna Grazia, Herishanu Yair, Shvidel Lev, Tadmor Tamar, Cortelezzi Agostino, Del Poeta Giovanni, Gaidano Gianluca, Di Raimondo Francesco, Neri Antonino, Ferrarini Manlio, Foà Robin, Polliack Aaron, Morabito Fortunato

机构信息

Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy.

Department of Medicine, Division of Hematology, Stanford University, Stanford, CA, USA.

出版信息

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20.

DOI:10.1038/s41375-018-0100-6
PMID:29588545
Abstract
摘要

相似文献

1
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.用于预测接受苯达莫司汀和利妥昔单抗一线治疗的慢性淋巴细胞白血病患者反应的生物学评分的验证。
Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20.
2
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.一线苯达莫司汀和利妥昔单抗联合化疗与氟达拉滨、环磷酰胺和利妥昔单抗治疗晚期慢性淋巴细胞白血病（CLL10）患者：一项国际、开放标签、随机、III 期、非劣效性临床试验。
Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20.
3
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病。
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
4
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.一项针对既往接受过治疗的慢性淋巴细胞白血病（CLL）患者的氟达拉滨、苯达莫司汀和利妥昔单抗（FBR）I-II期试验。
Oncotarget. 2017 Mar 28;8(13):22104-22112. doi: 10.18632/oncotarget.12054.
5
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.奥滨尤妥珠单抗联合苯达莫司汀治疗初治慢性淋巴细胞白血病患者：GREEN 研究的亚组分析。
Leukemia. 2018 Aug;32(8):1778-1786. doi: 10.1038/s41375-018-0146-5. Epub 2018 Apr 27.
6
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.肥胖和性别对接受基于利妥昔单抗的化疗免疫疗法的慢性淋巴细胞白血病（CLL）患者治疗结果的影响。
Leukemia. 2020 Apr;34(4):1177-1181. doi: 10.1038/s41375-019-0630-6. Epub 2019 Nov 14.
7
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.利妥昔单抗联合苯达莫司汀或苯丁酸氮芥治疗慢性淋巴细胞白血病：随机、开放标签 MABLE 研究的主要分析。
Haematologica. 2018 Apr;103(4):698-706. doi: 10.3324/haematol.2017.170480. Epub 2018 Feb 1.
8
A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.苯达莫司汀与利妥昔单抗用于合并症慢性淋巴细胞白血病患者的I期剂量范围研究。
Br J Haematol. 2017 Sep;178(5):820-823. doi: 10.1111/bjh.14171. Epub 2016 Jul 5.
9
Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.
Ophthalmology. 2021 Mar;128(3):402. doi: 10.1016/j.ophtha.2020.09.037.
10
Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.伴有合并症的慢性淋巴细胞白血病患者接受苯达莫司汀联合利妥昔单抗一线治疗的前瞻性观察性研究。
Leuk Res. 2019 Apr;79:17-21. doi: 10.1016/j.leukres.2019.02.002. Epub 2019 Feb 15.

引用本文的文献

1
Targeting the p53/xCT/GSH Axis with PRIMA-1 Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia.PRIMA-1联合柳氮磺胺吡啶靶向p53/xCT/谷胱甘肽轴在慢性淋巴细胞白血病中显示出治疗潜力。
Int J Mol Sci. 2025 Jun 10;26(12):5559. doi: 10.3390/ijms26125559.
2
Antitumor Effects of PRIMA-1 and PRIMA-1 (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?PRIMA-1 和 PRIMA-1（APR246）在血液系统恶性肿瘤中的抗肿瘤作用：仍然是突变型 P53 依赖性事件吗？
Cells. 2021 Jan 7;10(1):98. doi: 10.3390/cells10010098.
3
Heterogeneity of Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
癌症中突变的异质性与P53蛋白残余功能：这重要吗？
Front Oncol. 2020 Oct 28;10:593383. doi: 10.3389/fonc.2020.593383. eCollection 2020.
4
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.慢性淋巴细胞白血病中首次治疗时间和 P53 功能障碍：早期患者 O-CLL1 研究结果。
Sci Rep. 2020 Oct 28;10(1):18427. doi: 10.1038/s41598-020-75364-3.
5
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.复杂核型亚型与IGHV 突变状态的联合可确定慢性淋巴细胞白血病中的新预后和预测分组。
Br J Cancer. 2019 Jul;121(2):150-156. doi: 10.1038/s41416-019-0502-x. Epub 2019 Jun 18.